stockrow
Friday 6 November 2026
Export NVNO’s income statement to Excel — free account
enVVeno Medical Corporation
NVNO Healthcare Medical Devices
- EPS
- +22.0%
- Free cash flow
- +27.6%
Quarter to September 2026, against a year earlier
6.39
0.58
−8.32%
Follow NVNO
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 1 | 0 | 0 | 0 | — | — | — | — | — | — | 0 | (65.9%) | 7 | 17 | — | +140.0% | |
| Gross margin, % | (3.10) | 0.59 | 100.00 | 100.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | +3.1 pt | ||||||
| EBT | (6) | (8) | (13) | (8) | (9) | (17) | (25) | (24) | (22) | (19) | (16) | +14.9% | ||||||
| EBT margin, % | (711.07) | (1,845.89) | (6,989.66) | (24,440.38) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +711.1 pt | ||||||
| Net income | (3) | (8) | (13) | (8) | (9) | (17) | (25) | (24) | (22) | (19) | (16) | +21.4% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 113.90 | 60.30 | 17.44 | 1.73 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (491.89) | (1,115.49) | (1,535.09) | (421.05) | (264.56) | (66.67) | (76.88) | (67.02) | (44.56) | (33.06) | (23.45) | (25.9%) | ||||||
| Cash flow | (495.25) | (600.31) | (594.00) | (327.58) | (208.62) | (47.89) | (48.68) | (53.79) | (34.36) | (26.43) | (19.32) | (27.8%) | ||||||
| Capex | 18.13 | 22.19 | (1.16) | (20.22) | (4.90) | (1.49) | (0.36) | (0.09) | (0.08) | (0.01) | 0.00 | n/m | ||||||
| Free cash flow | (477.12) | (578.13) | (595.16) | (347.79) | (213.52) | (49.38) | (49.04) | (53.88) | (34.44) | (26.44) | (19.32) | (27.5%) | ||||||
| Book value | (611.51) | (1,590.07) | 190.32 | 54.99 | 192.88 | 219.90 | 120.70 | 131.77 | 86.04 | 46.06 | 24.35 | n/m | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | +63.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | 0.00 | 0.0 | |||||
| P/S | 110.75 | 110.75 | 73.97 | 46.38 | — | — | — | — | — | — | 23.74 | 85.5 | ||||||
| P/B | 0.00 | 0.00 | 6.78 | 8.75 | — | — | — | — | — | — | 0.26 | 3.9 | ||||||
| EV/Sales | 125.38 | 125.38 | 83.65 | 63.72 | — | — | — | — | — | — | (50.80) | 99.5 | ||||||
| EV/FCF | (7.17) | (7.17) | (2.45) | (1.90) | — | — | — | — | — | — | 0.71 | (4.7) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (3) | (4) | (6) | (6) | (8) | (12) | (16) | (19) | (17) | (16) | (13) | +18.4% | |||||
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | n/m | ||||||
| Free cash flow | (3) | (4) | (6) | (6) | (8) | (12) | (16) | (19) | (17) | (16) | (13) | +18.8% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | (1) | (3) | 1 | 0 | 6 | 53 | 38 | 46 | 42 | 27 | 16 | n/m | |||||
| Net debt | 0 | 2 | (3) | (1) | (9) | (55) | (39) | (46) | (43) | (28) | (18) | n/m | ||||||
| Shareholders’ equity | (4) | (11) | 2 | 1 | 7 | 54 | 39 | 46 | 42 | 27 | 17 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (186.62) | (412.80) | (566.40) | (218.07) | (139.46) | (48.44) | (49.66) | (52.09) | (46.63) | (52.26) | (60.00) | +134.4 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | 48.60 | 107.51 | 359.63 | (503.94) | (240.92) | (53.75) | (52.98) | (55.38) | (49.39) | (56.21) | (67.11) | (104.8) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | 12 | 9 | 12 | 19 | 24 | 30 | 31 | 37 | 33 | — | +13.5% | |||||
| Revenue/emp, $m | 0.00 | 0.04 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2019 · latest quarter Mar 2019 · fundamentals updated 2 Nov 2026
enVVeno Medical Corporation vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| INBS Intelligent Bio Solutions Inc. | $5.8M | — (loss-making) | — (loss-making) | +51.10% (above 0%: growing) | n/m | −31.59% (below 0%: shrinking) | 43.23% | (360.19%) | Compare |
| TBIO Telesis Bio Inc. | $5.3M | — (loss-making) | — (loss-making) | −71.85% (below 0%: shrinking) | n/m | −17.96% (below 0%: shrinking) | 64.43% | (349.74%) | Compare |
| VNRX VolitionRX Limited | $5.3M | — (loss-making) | — (loss-making) | −1.97% (below 0%: shrinking) | n/m | +18.58% (above 0%: growing) | 100.00% | (1,042.39%) | Compare |
| BDMD Baird Medical Investment Holdings Limited | $5.0M | — (loss-making) | — | — | n/m | −598.12% (below 0%: shrinking) | — | — | Compare |
| NVNO enVVeno Medical Corporation | $4.8M | — (loss-making) | — (loss-making) | +0.32% (above 0%: growing) | n/m | +27.64% (above 0%: growing) | 0.00% | 0.00% | |
| TNON Tenon Medical, Inc. | $4.4M | — (loss-making) | — (loss-making) | +126.77% (above 0%: growing) | n/m | −21.78% (below 0%: shrinking) | 63.64% | (262.24%) | Compare |
| WOK WORK Medical Technology Group LTD | $4.1M | — | — | — | — | −948.94% (below 0%: shrinking) | — | — | Compare |
| TRIB Trinity Biotech PLC | $3.8M | — (loss-making) | — (loss-making) | +43.28% (above 0%: growing) | n/m | +75.24% (above 0%: growing) | 35.43% | (24.53%) | Compare |
| XAIR Beyond Air, Inc. | $3.6M | — (loss-making) | — (loss-making) | +0.45% (above 0%: growing) | n/m | −9.10% (below 0%: shrinking) | 12.73% | (373.98%) | Compare |
| Median of peers | $4.7M | — | — | +21.87% | — | −19.87% | 53.44% | (354.96%) |
Pay and ownership Proxy statement filed 29 October 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 583.76k | (166.04k) | 6.29 |
| 2024 | 1.16m | 218.41k | 59.22 |
| 2023 | 1.87m | 2.15m | 100.78 |
Ownership
Directors and executive officers, together
14.80%
Thomas A. Satterfield, Jr.
7.50%
Robert A. Berman
6.60%
Kingdon Capital Management, L.L.C.
5.20%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement